Has Andrea Pekarek received payments from drug or device companies?

Yes. Drug and device makers reported $3,785 in general payments to Andrea Pekarek across 186 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrea Pekarek did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrea Pekarek come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrea Pekarek

Family Medicine · Ann Arbor, MINPI 1700387784

Payments from drug & device makers

$3,785in general payments, 2019–2025

Across 186 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$369
Takeda Pharmaceuticals U.S.A., Inc.$281
Amgen$245
Gilead$195
Sanofi-aventis U.S. LLC$188
Pfizer$163
plus $2K from 43 others

What the payments were for

Food & beverage$3,49892%
Education$2878%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	22	$369
Takeda Pharmaceuticals U.S.A., Inc.	8	$281
Amgen	13	$245
Gilead(2 entities)	8	$195
Sanofi-aventis U.S. LLC	2	$188
Pfizer	10	$163
AstraZeneca(2 entities)	9	$162
AbbVie	5	$130
Seagen Inc.	6	$120
Johnson & Johnson(2 entities)	7	$119
Daiichi Sankyo Inc.	6	$112
Sanofi	5	$111
Lilly USA, LLC	7	$109
Regeneron Healthcare Solutions, Inc.	4	$104
Bristol Myers Squibb	6	$95
Otsuka America Pharmaceutical, Inc.	4	$86
Beigene USA, Inc.	4	$71
Astellas Pharma US Inc	4	$70
Pharmacyclics LLC, An Abbvie Company	3	$68
Eisai Inc.	3	$67
E.r. Squibb & Sons, L.L.C.	4	$66
AVEO Pharmaceuticals, Inc.	4	$60
Array Biopharma Inc	3	$59
Servier Pharmaceuticals LLC	3	$57
Merck	2	$52
Incyte Corporation	3	$48
Rigel Pharmaceuticals, Inc.	2	$43
Genentech USA, Inc.	2	$40
Taiho Oncology, Inc.	2	$40
Morphosys, US Inc.	2	$37
ADC Therapeutics America, Inc.	2	$36
Sobi, Inc	2	$36
GSK	2	$35
Adaptive Biotechnologies Corporation	2	$29
Alkermes, Inc.	1	$26
AMAG Pharmaceuticals, Inc.	1	$24
Myriad Genetic Laboratories, Inc.	1	$23
Sirtex Medical Inc	1	$21
Ipsen Biopharmaceuticals, Inc	1	$21
CTI Biopharma Corp.	1	$20
Pharmaessentia USA Corporation	1	$20
EMD Serono, Inc.	1	$19
Apellis Pharmaceuticals, Inc.	1	$18
Karyopharm Therapeutics Inc.	1	$18
Sumitomo Pharma America, Inc.	1	$17
Exelixis Inc.	1	$16
Deciphera Pharmaceuticals Inc.	1	$16
Stemline Therapeutics Inc.	1	$15
Puma Biotechnology, Inc.	1	$12

How this compares

$3,785 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	13	$483

Paid to pharmacies, not to this prescriber.

Other family medicine in Ann Arbor

Shathabish KariyannaAnn Arbor$119K
David SerlinAnn Arbor$27K
Angela McGradyAnn Arbor$19K
Derrick WilliamsonSouthfield$9.9M
Rebecca RivardRoseville$7M
Paul BensonBerkley$4.2M
Michael HafranEast Lansing$2.7M
Mitzie HewittBuckley$1.3M
Loren ChudlerSouthfield$1.3M
Solomon AmsterWhite Lake$981K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →